Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Short Interest Update

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 15,300,300 shares, a drop of 79.5% from the March 15th total of 74,612,700 shares. Based on an average daily volume of 1,500 shares, the short-interest ratio is currently 10,200.2 days. Approximately 0.1% of the shares of the company are short sold.

Sino Biopharmaceutical Trading Up 3.0 %

SBMFF traded up $0.01 on Monday, hitting $0.47. 4,500 shares of the stock traded hands, compared to its average volume of 2,314. The business has a fifty day moving average price of $0.42 and a two-hundred day moving average price of $0.43. The company has a current ratio of 1.15, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. Sino Biopharmaceutical has a 52 week low of $0.31 and a 52 week high of $0.47.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.